News and Information
The Iowa Economic Development Authority Board appointed Susan Wood, CEO of Vida Diagnostics, to the Iowa Innovation Council.
A Coralville-based medical software startup born out of the University of Iowa has attracted $2.5 million in funding.
Vida Diagnostics said Wednesday that it has received $2 million in funding from Next Level Ventures, a Des Moines venture capital firm created to invest in Iowa companies. That investment comes on top of a $500,000 loan Vida received from the state.
Wood was one of 45 women entrepreneurs, academics and others named finalists in 10 categories of Technology Association of Iowa's seventh annual Women of Innovation awards.
Winners will be announced at a ceremony on Nov. 11 at Prairie Meadows Event and Conference Center in Altoona.
"We put the highest priority on diversity and Women of Innovation gives us the annual opportunity to honor accomplishments of the women of Iowa," TAI President Brian Waller said in a release. "Each finalist is extremely accomplished and extraordinary and we are excited to honor them for their individual achievement and impact on Iowa."
VIDA Diagnostics Releases Next Generation Software for Distributed Viewing and Workflow Enhancements
Apollo™ 2.0 Released Enhancing Clinical Experience
Chicago, IL – October 28, 2013 – VIDA Diagnostics, a leading provider of quantitative imaging and informatics services to aid diagnosis and treatment planning for patients with pulmonary disease, announces the release of Apollo 2.0, here at the 2013 American Association of Chest Physicians Conference.
Combined use of market-leading diagnostic technologies opens door to treatment options
Minneapolis, MN – April 11, 2013 – Covidien (NYSE: COV), a leading global provider of healthcare products, today announced an agreement with VIDA Diagnostics, a pioneer in quantitative pulmonary imaging analysis software. Under the agreement, Covidien will distribute VIDA’s Apollo® pulmonary imaging software services.
Cupertino, CA – October 15, 2012: VIDA Diagnostics, Inc. today announced
the expansion of their branch office in Cupertino, CA as part of its continued
efforts to provide the most innovative services and technologies to its customers.
The office is located at:
VIDA Diagnostics, Inc.
21631 Stevens Creek Blvd.
Cupertino, CA 95014
VIDA Diagnostics introduces its next generation software as a service platform, Apollo® 1.2
VIENNA, Sept. 3, 2012 /PRNewswire/ -- VIDA Diagnostics, a leading developer of quantitative imaging analysis software for the diagnosis and treatment planning of major pulmonary disease, announced today the release and commercial availability of Apollo® 1.2, here at the European Respiratory Society (ERS) meeting in Vienna, Austria.
COPDGene Study Generates New Insights Into COPD
CHEST Physician Article | 04.23.12
In September 2007, the largest study of COPD in the United States was funded by the NHLBI to broadly address unanswered questions about the causes of COPD. The study was funded as paired projects at National Jewish Health in Denver, Colorado, and Brigham and Women’s Hospital in Boston, Massachusetts, under the direction of Co-Principal Investigators Dr. James D. Crapo, FCCP; and Dr. Edwin K. Silverman, PhD.
FOR IMMEDIATE RELASE - Coralville, IA – March 28, 2012 - VIDA Diagnostics, a leading developer of quantitative pulmonary imaging software, announced today that the company has appointed Philippe Raffy, Ph.D. as Chief Technology Officer (CTO). Dr. Raffy's inclusion to the VIDA management team strengthens the technical leadership and expertise in pulmonary image analysis.
CT scans are being analyzed by the Quantitative Imaging Lab at National Jewish, using the VIDA software, for automated measures of emphysema, gas trapping, and airway disease
Mountain View, CA – February 21, 2012: The cover of The American Journal of Respiratory and Critical Care Medicine (February 15, 2012; 185 (4)) features images from VIDA Diagnostics' proprietary quantitative imaging software, Apollo.
The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.
The cover images are taken from Figure 2 in the Pulmonary Perspective by Jarjour and colleagues beginning on page 356. The panels show quantitative computerized tomography of subjects with mild asthma (left) and severe asthma (right). The lobes are color coded.
VIDA Diagnostics Opens First Branch Office in Silicon Valley
Mountain View, CA – February 3, 2012: VIDA Diagnostics, Inc. today announced the opening of a new branch office in Mountain View, CA in Silicon Valley as part of the company's initiative to develop key growth markets and support its global commercialization strategy.
The new office is the first branch office established outside of VIDA’s corporate headquarters in Coralville, IA.
Vida Diagnostics, Inc.
800 West El Camino Real
Mountain View, CA 94040
Uptake Medical Announces Successful Completion of Series C Financing
Funding Will Support Commercialization of InterVapor for Treatment of Severe Emphysema
TUSTIN, Calif., Jan. 9, 2012 – Uptake Medical® today announced that it has closed on a Series C funding round. The round was led by Singapore-based Crescent Point Group, with existing investors, Maverick Capital, ONSET Ventures, GBS Venture Partners, WRF Capital, Arboretum Ventures and Affinity Capital, making additional investments. Sami Sindi, Crescent Point managing partner, will join the Uptake Medical board of directors. Moelis & Company acted as financial advisor to the company in connection with the funding.Read Release »
Uptake Medical Announces TGA Approval of InterVapor for Patients With Severe Emphysema
TUSTIN, Calif., Dec. 21, 2011 – Uptake Medical® today announced that it received Australian Therapeutic Goods Administration (TGA) approval for its InterVapor™ System for endoscopic lung volume reduction for the treatment of severe emphysema. InterVapor is the first non-surgical, endoscopic lung volume reduction system for the treatment of severe emphysema that uses the body’s natural healing processes without leaving implants or foreign materials in the lung.Read Release »
Uptake Medical Announces First Commerical Use of InterVapor for Patients with Severe Emphysema
New treatment provides clinically meaningful improvements inlung function and quality of life
TUSTIN, Calif., Nov. 29, 2011 – Uptake Medical® today announced the first commercial use of theInterVapor™ System for endoscopic lung volume reduction in a patient with severe emphysema. Read Article »
VIDA® Diagnostics' Software, Apollo®, Installed at U of Florence (Italy)
VIDA® Diagnostics’ quantitative pulmonary imaging software, Apollo®, was recently installed at the University of Florence, Italy, for usage in clinical assessment of Chronic Obstructive Pulmonary Disease (COPD) phenotypes. Read Article »
VIDA'S APOLLO SOFTWARE FEATURED IN Pulm�o RJ (Brazil)
The cover of the Pulm�o RJ features an image from VIDA's proprietary quanititative imaging software, Apollo.
The corresponding journal article, "Tratamento endosc�pico do enfisema (Bronchoscopic treatment of emphysema)", was published by Hugo G. de Oliveira1,2, Silvia M. de Oliveira2, Amarilio V. de Macedo Neto1,2. Hospital de Cl�nicas de Porto Alegre, HCPA, Universidade Federal do Rio Grande do Sul, UFRGS, Porto Alegre (RS) Brasil. (Pulm�o RJ 2011;20(2):2-7). Read article and its translation on VIDA's Clinical Validation/Peer Reviewed Literature page here >>
VIDA Diagnostics Earns ISO 13485 and CE Certifications
Coralville, IA – September 19, 2011 - VIDA Diagnostics, a leading developer of quantitative pulmonary imaging software, announced today that the company has achieved International Organization for Standardization (ISO 13485) certification and CE certification for its flagship product, Apollo®. The CE certification permits VIDA to sell Apollo for clinical use in the European Economic Area (EEA) and Switzerland. Apollo currently has FDA 510(k) approval for clinical use in the U.S.
VIDA DIAGNOSTICS FEATURED IN THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
June 3, 2011 - VIDA Diagnostics is prominently featured in a new journal article, 'Lung imaging in asthmatic patients: The picture is clearer', (DOI: 10.1016/j.jaci.2011.04.051) published by Mario Castro, MD (Washington University School of Medicine) in the latest Journal of Allergy and Clinical Immunology.
VIDA DIAGNOSTICS LAUNCHES APOLLO® PULMONARY ANALYSIS SOFTWARE FOR MAJOR LUNG DISEASE AT AMERICAN THORACIC SOCIETY MEETING
Quantitative Pulmonary Solution for Clinical Evaluation of COPD, Asthma and Lung Cancer Installed at Leading Pulmonology Centers
DENVER, May 16, 2011 – VIDA Diagnostics, a leading developer of quantitative pulmonary imaging software, announced today the launch of its new Apollo® Software for the evaluation of pulmonary disease including chronic obstructive pulmonary disease (COPD), asthma, and lung cancer, here at the 2011 International Conference of the American Thoracic Society (ATS). Read Press Release»
CT Scans Cut Lung Cancer Deaths, Study Finds
A trial has shown that early detection, using annual CT scans rather than X-rays, can sharply reduce deaths.
NEW YORK TIMES - WASHINGTON - Nov. 4 � Annual CT scans of current and former heavy smokers reduced their risk of death from lung cancer by 20 percent, a huge government-financed study has found. Even more surprising, the scans seem to reduce the risks of death from other causes as well, suggesting that the scans could be catching other illnesses.
Coralville, IA – November 1, 2010 - VIDA Diagnostics, Inc., a leader in quantitative pulmonary image analysis, announces the introduction of its Apollo® Pulmonary Evaluation Software, a comprehensive quantitative software solution for the analysis of major lung diseases, including COPD, asthma, and lung cancer, at the Chest 2010 meeting in Vancouver, BC.
Read Press Release
VIDA in the News
VIDA Diagnostics Screenshot Featured
VIDA Dignostics image was featured on cover of American Journal of Respiratory and Critical Care Medicine Vol 180, Issue 7, October 1, 2009.
The image was used inconjunction with the feature article, "New and Current Clinical Imaging Techniques to Study Chronic Obstructive Pulmonary Disease"